Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022
Rebecca Amati, Anja Frei, Marco Kaufmann, Serena Sabatini, Céline Pellaton, Jan Fehr, Emiliano Albanese, Milo A. Puhan
Abstract
Functional immunity (defined here as serum neutralising capacity) critically contributes to conferring protection against SARS-CoV-2 infection and severe COVID-19. This cross-sectional analysis of a prospective, population-based cohort study included 1,894 randomly-selected 16 to 99-year-old participants from two Swiss cantons in March 2022. Of these, 97.6% (95% CI: 96.8-98.2%) had anti-spike IgG antibodies, and neutralising capacity was respectively observed for 94%, 92% and 88% against wild-type SARS-CoV-2, Delta and Omicron variants. Studying functional immunity to inform and monitor vaccination campaigns is crucial.
Topics & Concepts
ImmunityBooster (rocketry)MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VaccinationPopulationVirologyCohortAntibodyCoronavirus disease 2019 (COVID-19)ImmunologyHerd immunityProspective cohort studyHumoral immunityImmune systemInternal medicineEnvironmental healthDiseaseInfectious disease (medical specialty)PhysicsAstronomySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19